ABIOMED Stock Price, News & Analysis (NASDAQ:ABMD)

$270.48 +2.74 (+1.02 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$270.48
Today's Range$264.45 - $273.27
52-Week Range$114.28 - $274.00
Volume475,400 shs
Average Volume414,851 shs
Market Capitalization$11.99 billion
P/E Ratio109.12
Dividend YieldN/A
Beta0.36

About ABIOMED (NASDAQ:ABMD)

ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:ABMD
CUSIP00365410
Phone+1-978-7775410

Debt

Debt-to-Equity RatioN/A
Current Ratio5.60%
Quick Ratio4.98%

Price-To-Earnings

Trailing P/E Ratio109.117886178862
Forward P/E Ratio113.17
P/E Growth3.55

Sales & Book Value

Annual Sales$445.30 million
Price / Sales26.90
Cash Flow$1.35 per share
Price / Cash199.90
Book Value$14.28 per share
Price / Book18.94

Profitability

Trailing EPS$2.46
Net Income$52.11 million
Net Margins16.58%
Return on Equity15.54%
Return on Assets13.40%

Miscellaneous

Employees908
Outstanding Shares44,280,000

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings data on Thursday, February, 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.50 by $0.20. The medical equipment provider earned $154 million during the quarter, compared to analyst estimates of $154 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company's revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter last year, the business posted $0.34 EPS. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2018?

8 brokers have issued 1-year price objectives for ABIOMED's shares. Their forecasts range from $259.00 to $370.00. On average, they expect ABIOMED's stock price to reach $301.50 in the next twelve months. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
  • David M. Weber, Chief Operating Officer (Age 55)
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations (Age 65)
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing (Age 44)
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing (Age 53)
  • Dorothy E. Puhy, Lead Independent Director (Age 66)
  • Jeannine M. Rivet, Independent Director (Age 69)
  • Eric A. Rose M.D., Independent Director (Age 66)
  • Martin P. Sutter, Independent Director (Age 62)

Who owns ABIOMED stock?

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.96%), Palo Alto Investors LLC (3.58%), Brown Capital Management LLC (3.23%), Renaissance Technologies LLC (2.45%), American Century Companies Inc. (2.18%) and William Blair Investment Management LLC (2.17%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Essex Woodlands Management Inc., Wells Fargo & Company MN, Frontier Capital Management Co. LLC, Two Sigma Investments LP, Castleark Management LLC, Guggenheim Capital LLC and State Treasurer State of Michigan. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Paul Thomas. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Perceptive Advisors LLC, Carillon Tower Advisers Inc., Fred Alger Management Inc., Standard Life Aberdeen plc, Millennium Management LLC, BlackRock Inc. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $270.48.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $11.99 billion and generates $445.30 million in revenue each year. The medical equipment provider earns $52.11 million in net income (profit) each year or $2.46 on an earnings per share basis. ABIOMED employs 908 workers across the globe.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS, MA 01923-2575, United States. The medical equipment provider can be reached via phone at +1-978-7775410 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (ABMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ABIOMED (NASDAQ:ABMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.712.752.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $301.50$210.00$180.43$157.50
Price Target Upside: 12.61% upside7.03% downside6.47% downside4.30% upside

ABIOMED (NASDAQ:ABMD) Consensus Price Target History

Price Target History for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ:ABMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/AView Rating Details
2/4/2018BTIG ResearchReiterated RatingHoldHighView Rating Details
2/2/2018Leerink SwannBoost Price TargetOutperform$300.00LowView Rating Details
2/2/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$204.00 -> $259.00LowView Rating Details
2/2/2018GuggenheimReiterated RatingBuy$280.00MediumView Rating Details
2/1/2018Jefferies GroupReiterated RatingBuy$300.00MediumView Rating Details
2/1/2018Piper Jaffray CompaniesReiterated RatingOverweight -> Positive$220.00 -> $300.00MediumView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
4/10/2016BenchmarkReiterated RatingBuy$145.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

ABIOMED (NASDAQ:ABMD) Earnings History and Estimates Chart

Earnings by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ ABMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.56N/AView Earnings Details
2/1/2018Q3 2018$0.50$0.70$154.00 million$154.00 millionViewN/AView Earnings Details
10/26/2017Q2 2018$0.38$0.54$131.18 million$132.80 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
11/4/2010Q2 2011($0.14)($0.09)ViewN/AView Earnings Details
8/4/2010Q1 2011($0.14)($0.14)ViewN/AView Earnings Details
5/19/2010Q4 2010($0.12)($0.11)ViewN/AView Earnings Details
2/4/2010Q3 2010($0.18)($0.11)ViewN/AView Earnings Details
11/5/2009Q2 2010($0.21)($0.21)ViewN/AView Earnings Details
8/6/2009Q1 2010($0.20)($0.20)ViewN/AView Earnings Details
5/12/2009Q4 2009($0.17)($0.22)ViewN/AView Earnings Details
2/5/2009Q3 2009($0.17)($0.20)ViewN/AView Earnings Details
11/10/2008Q2 2009($0.21)($0.18)ViewN/AView Earnings Details
8/7/2008Q1 2009($0.21)($0.28)ViewN/AView Earnings Details
5/21/2008Q4 2008($0.19)($0.25)ViewN/AView Earnings Details
2/7/2008Q3 2008($0.20)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ABIOMED (NASDAQ:ABMD) Earnings Estimates

2018 EPS Consensus Estimate: $1.86
2019 EPS Consensus Estimate: $2.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.58$0.50
Q4 20183$0.52$0.66$0.60
Q1 20192$0.58$0.68$0.63
Q2 20192$0.66$0.68$0.67
Q3 20191$0.62$0.62$0.62
Q4 20192$0.78$0.82$0.80
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for ABIOMED (NASDAQ:ABMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ABIOMED (NASDAQ ABMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 86.99%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ ABMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/30/2017Dorothy E PuhyDirectorSell6,364$179.08$1,139,665.1239,532View SEC Filing  
10/30/2017Michael G HowleyVPSell10,000$178.64$1,786,400.0056,757View SEC Filing  
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.9413,634View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.6224,652View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.0012,172View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00125,122View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.2462,105View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50123,771View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.0038,249View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.0048,305View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.0066,307View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.0032,749View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.0021,259View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73215,488View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38215,782View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00215,782View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.4024,749View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.0033,811View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.6065,558View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20325,778View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.0065,558View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.0065,234View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74100,159View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24116,783View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90117,411View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00121,676View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.0028,811View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.0061,186View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.0062,268View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.0052,668View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.0047,792View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.0058,941View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55113,411View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.0073,614View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.0052,190View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.0473,614View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.0054,242View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20125,761View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.9098,392View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31125,761View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.0066,190View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.4098,392View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.0062,190View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00239,718View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50130,482View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.9874,486View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02260,912View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.4094,205View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.0066,929View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00126,907View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.0089,718View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.9089,718View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00133,407View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.0068,753View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00137,807View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.0077,153View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.4066,929View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.2098,552View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ABIOMED (NASDAQ ABMD) News Headlines

Source:
DateHeadline
Here are 5 top stock picks from Wall Street analysts for a choppy marketHere are 5 top stock picks from Wall Street analysts for a choppy market
finance.yahoo.com - February 20 at 9:22 AM
Abiomed Hits New 52-Week High: 4 Factors Driving the StockAbiomed Hits New 52-Week High: 4 Factors Driving the Stock
www.zacks.com - February 19 at 9:31 AM
ABIOMED (ABMD) Receives Buy Rating from SunTrust BanksABIOMED (ABMD) Receives Buy Rating from SunTrust Banks
www.americanbankingnews.com - February 17 at 6:24 AM
Abiomed's Extended FDA Nod for Impella Refines PCI DiagnosisAbiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
finance.yahoo.com - February 16 at 4:13 PM
Abiomeds Extended FDA Nod for Impella Refines PCI DiagnosisAbiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
www.zacks.com - February 16 at 9:23 AM
Abiomed (ABMD) Granted Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention ... - StreetInsider.comAbiomed (ABMD) Granted Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention ... - StreetInsider.com
www.streetinsider.com - February 14 at 3:23 PM
Abiomed's Extended FDA Nod for Impella Boosts Women HealthAbiomed's Extended FDA Nod for Impella Boosts Women Health
finance.yahoo.com - February 14 at 3:23 PM
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) ProceduresAbiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
finance.yahoo.com - February 14 at 3:23 PM
Abiomed (ABMD) Announces Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic - StreetInsider.comAbiomed (ABMD) Announces Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic - StreetInsider.com
www.streetinsider.com - February 14 at 6:11 AM
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic ShockAbiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
finance.yahoo.com - February 13 at 3:21 PM
Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart RecoveryAbiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart Recovery
finance.yahoo.com - February 13 at 3:21 PM
ABIOMED, Inc. (ABMD) Given Consensus Rating of "Buy" by BrokeragesABIOMED, Inc. (ABMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 9 at 8:30 AM
Head-To-Head Contrast: Hologic (HOLX) & ABIOMED (ABMD)Head-To-Head Contrast: Hologic (HOLX) & ABIOMED (ABMD)
www.americanbankingnews.com - February 8 at 7:02 PM
ABIOMED (ABMD) Cut to "Hold" at Zacks Investment ResearchABIOMED (ABMD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 7:54 PM
Q1 2019 EPS Estimates for ABIOMED, Inc. (ABMD) Boosted by Leerink SwannQ1 2019 EPS Estimates for ABIOMED, Inc. (ABMD) Boosted by Leerink Swann
www.americanbankingnews.com - February 5 at 8:48 AM
ABIOMED, Inc. (ABMD) Expected to Post Q2 2019 Earnings of $0.66 Per ShareABIOMED, Inc. (ABMD) Expected to Post Q2 2019 Earnings of $0.66 Per Share
www.americanbankingnews.com - February 5 at 7:58 AM
Q4 2018 EPS Estimates for ABIOMED, Inc. Increased by Jefferies Group (ABMD)Q4 2018 EPS Estimates for ABIOMED, Inc. Increased by Jefferies Group (ABMD)
www.americanbankingnews.com - February 5 at 7:41 AM
ABIOMEDs (ABMD) "Hold" Rating Reaffirmed at BTIG ResearchABIOMED's (ABMD) "Hold" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - February 4 at 11:44 AM
ABIOMED (ABMD) Stock Rating Reaffirmed by GuggenheimABIOMED (ABMD) Stock Rating Reaffirmed by Guggenheim
www.americanbankingnews.com - February 3 at 10:58 PM
 Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Earnings of $0.59 Per Share Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Earnings of $0.59 Per Share
www.americanbankingnews.com - February 3 at 11:58 AM
ABIOMED (ABMD) Price Target Raised to $259.00 at Morgan StanleyABIOMED (ABMD) Price Target Raised to $259.00 at Morgan Stanley
www.americanbankingnews.com - February 2 at 11:32 PM
ABIOMED (ABMD) Price Target Increased to $300.00 by Analysts at Leerink SwannABIOMED (ABMD) Price Target Increased to $300.00 by Analysts at Leerink Swann
www.americanbankingnews.com - February 2 at 4:48 PM
Commit To Purchase ABIOMED At $195, Earn 6.2% Annualized Using Options - NasdaqCommit To Purchase ABIOMED At $195, Earn 6.2% Annualized Using Options - Nasdaq
www.nasdaq.com - February 2 at 3:22 PM
Abiomed, Inc Pumps Out Record Results - Motley FoolAbiomed, Inc Pumps Out Record Results - Motley Fool
www.fool.com - February 2 at 3:22 PM
ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3
finance.yahoo.com - February 2 at 3:22 PM
Abiomed, Inc Pumps Out Record ResultsAbiomed, Inc Pumps Out Record Results
finance.yahoo.com - February 2 at 5:58 AM
ABIOMED (ABMD) Rating Reiterated by Jefferies GroupABIOMED (ABMD) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - February 1 at 8:14 PM
ABIOMED (ABMD) Earns "Positive" Rating from Piper Jaffray CompaniesABIOMED (ABMD) Earns "Positive" Rating from Piper Jaffray Companies
www.americanbankingnews.com - February 1 at 4:58 PM
Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior YearAbiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
finance.yahoo.com - February 1 at 3:21 PM
ABIOMED, Inc. to Host Earnings CallABIOMED, Inc. to Host Earnings Call
finance.yahoo.com - February 1 at 3:21 PM
ABIOMED (ABMD) Announces Quarterly  Earnings ResultsABIOMED (ABMD) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 1 at 11:14 AM
ABIOMED (ABMD) Set to Announce Earnings on ThursdayABIOMED (ABMD) Set to Announce Earnings on Thursday
www.americanbankingnews.com - January 25 at 2:02 AM
ABIOMED (ABMD) Given New $265.00 Price Target at Leerink SwannABIOMED (ABMD) Given New $265.00 Price Target at Leerink Swann
www.americanbankingnews.com - January 20 at 3:28 PM
ABIOMED (ABMD) Raised to "Strong-Buy" at BidaskClubABIOMED (ABMD) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - January 20 at 12:33 PM
Breakout Watch: 99 A+ Funds Have Positions In This IBD 50 StockBreakout Watch: 99 A+ Funds Have Positions In This IBD 50 Stock
finance.yahoo.com - January 18 at 11:53 AM
Stocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day SupportStocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day Support
finance.yahoo.com - January 16 at 3:31 PM
ABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by AnalystsABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 15 at 7:42 AM
ABIOMED (ABMD) PT Raised to $250.00ABIOMED (ABMD) PT Raised to $250.00
www.americanbankingnews.com - January 14 at 7:28 AM
Abiomed At Top End Of Buy Zone With Earnings DueAbiomed At Top End Of Buy Zone With Earnings Due
finance.yahoo.com - January 10 at 11:37 AM
Phibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails - NasdaqPhibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails - Nasdaq
www.nasdaq.com - January 9 at 3:33 PM
Abiomed (ABMD) Prelim. Q3 Revenue Tops Views - StreetInsider.comAbiomed (ABMD) Prelim. Q3 Revenue Tops Views - StreetInsider.com
www.streetinsider.com - January 8 at 3:37 PM
Is ABIOMED Inc’s (NASDAQ:ABMD) Liquidity As Good As Its Solvency?Is ABIOMED Inc’s (NASDAQ:ABMD) Liquidity As Good As Its Solvency?
finance.yahoo.com - January 8 at 10:59 AM
Entellus (ENTL) Nears 52-Week High: What's Driving It?Entellus (ENTL) Nears 52-Week High: What's Driving It?
finance.yahoo.com - January 3 at 3:32 PM
5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now
www.zacks.com - January 2 at 11:14 AM
$147.65 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter$147.65 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - January 2 at 6:58 AM
Comparing ABIOMED (ABMD) and Mazor Robotics (MZOR)Comparing ABIOMED (ABMD) and Mazor Robotics (MZOR)
www.americanbankingnews.com - January 1 at 9:10 PM
Abiomed to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Abiomed to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 29 at 3:32 PM
Abiomed to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAbiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 29 at 10:55 AM
ABIOMED (ABMD) Lifted to Buy at Zacks Investment ResearchABIOMED (ABMD) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - December 29 at 9:30 AM
ABIOMED (ABMD) Given New $220.00 Price Target at Jefferies GroupABIOMED (ABMD) Given New $220.00 Price Target at Jefferies Group
www.americanbankingnews.com - December 21 at 9:36 AM

SEC Filings

ABIOMED (NASDAQ:ABMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ABIOMED (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ABIOMED (NASDAQ ABMD) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.